Tanespimycin (KOS-953, 17-AAG)
Updated: Jul 22, 2010
| Brand Name: | |
| Generic Name: | tanespimycin |
| Code Names: | KOS-953, 17-AAG |
| Company: | Bristol-Myers Squibb / Kosan Biosciences |
| FDA Clinical Phase: | clinical development halted |
Description:
A benzoquinone antineoplastic antibiotic derived from the antineoplastic antibiotic geldanamycin. Tanespimycin binds to and inhibits the cytosolic chaperone functions of heat shock protein 90 (HSP90). HSP90 maintains the stability and functional shape of many oncogenic signaling proteins; the inhibition of HSP90 promotes the proteasomal degradation of oncogenic signaling proteins that may be overexpressed by tumor cells.
Clinical Trials:
For a list of clinical trials studying tanespimycin for the treatment of multiple myeloma, see ClinicalTrials.gov.
Beacon news: BMS Halts Development Of Tanespimycin
Related Articles:
- Bristol-Myers Squibb Halts Development of Tanespimycin
- Tanespimycin-Velcade Combination Proves Highly Effective In Multiple Myeloma Patients (ASH 2009)
- Phase 3 Trials Of Hsp90 Inhibitors In Cancer Patients Underway
- Trial Investigates Effects Of Tanespimycin-Velcade Combination Treatment (ASCO 2009)
- New Myeloma Drugs Target Different Mechanisms: Misfolded Proteins
Leave a comment